Maxwell Zachary Price is a graduate of Columbia College, Columbia University in the City of New York concentrating in Computational Neuroscience. He is currently a research scientist at Hackensack University Medical Center where he has received his medical school and Masters of Public Health in Biostatistics training. Maxwell has published numerous peer-reviewed articles in prestigious journals, such as Lancet, British Medical Journal, CNS Drugs, The Journal of Clinical Psychiatry, and Nature covering a range of topics including Attention Deficit Hyperactivity Disorder, Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Alzheimer’s Disease, Metabolic Syndrome, Addiction, and Borderline Personality.
His impactful research has been covered by international medical news outlets, such as Medscape. He has patented a novel treatment for carcinogenic harmful blooms and has researched a novel treatment approach to Multiple Sclerosis using an angiogenesis inhibitor. Maxwell has developed a concept for the launch of an artificial intelligence psychiatry platform to assist practitioners and patients with more accurate diagnoses and treatment algorithms and has published a patent enabling the first oral medication for Treatment-Resistant Depression in over 20 years. Maxwell has presented his research at Psych Congress and Neuroscience Education Institute, where his poster won first place in 2023.
